THC Reagent Kits
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of the Navy, specifically NAVSUP FLT LOG CTR NORFOLK, is soliciting proposals for FDA and Quality Management Documented THC9-COOH Immunoassay Reagent Kits. These kits are required by the Drug Demand Reduction Program (DDRP) for use with existing Beckman Coulter AU5800 series systems to detect THC9-COOH in human urine samples. This is an Unrestricted Firm Fixed Price solicitation. Step One proposals are due April 22, 2026, and Step Two proposals are due May 15, 2026.
Scope of Work
This requirement is for DELTA-9-TETRAHYDROCANNABINOL-11-CARBOXYLIC ACID (THC9-COOH) Immunoassay Reagent Kits. Key requirements include:
- Compatibility: Must be compatible with Beckman Coulter AU5800 Series Clinical Chemistry Analyzers.
- Quality Standards: Kits must be FDA cleared and manufactured under Good Manufacturing Practices (GMP).
- Shelf Life: Minimum 180 days for unopened components and 14 days for opened components.
- Performance: Reagents must meet specific sensitivity, specificity, and cross-reactivity requirements detailed in the Statement of Work (SOW).
- Offeror Eligibility: Offerors must be Original Equipment Manufacturers (OEMs), authorized dealers, distributors, or resellers, capable of providing OEM parameters, quality controls, and services.
- Packaging: Must be suitable for biological reagents and comply with ASTM D 3951-15.
Contract Details
- Contract Type: Firm Fixed Price.
- Period of Performance: Five (5) years, from July 1, 2026, to June 30, 2031.
- Estimated Workload: The contract is expected to accommodate up to 500,000 tests per month, totaling an estimated 30,000,000 kits over the five-year period.
- NAICS Code: 325413 (In Vitro Diagnostic Substance Manufacturing).
- Place of Performance: Portsmouth, VA, United States.
Submission & Evaluation
- Solicitation Issue Date: May 15, 2026 (Notice published April 16, 2026).
- Questions Submission Deadline: May 15, 2026, 12:00 AM. Offerors are encouraged to submit consolidated questions via email.
- Proposal Due Dates:
- Step One (Technical Approach): April 22, 2026. This is a Pass/Fail evaluation covering FDA/ISO certification, SOW compliance, and reagent preparation information.
- Step Two (Performance & Price): May 15, 2026, 12:00 AM.
- Evaluation Process: Award will be made using a tradeoff process, considering technical approach, performance, small business participation, and price.
- Step Two evaluation includes Minimum Requirements (Pass/Fail), Enhancing Factors, Past Performance, and Business Proposal/Price.
- Enhancing Factors are the most important, followed by Past Performance, then Price.
- Set-Aside: Unrestricted.
Points of Contact
- Primary: Nicholas Haas (nicholas.a.haas10.civ@us.navy.mil, 717-891-4098)
- Secondary: Gerald Bowne (gerald.l.bowne.civ@us.navy.mil)